Latest / Pharmacy Podcast Network / Demystifying Medicaid Coverage and Reimbursement for Pharmacogenomics Testing | Precision Health and PGx Podcast
Transcript
- 0:06Speaker 1: As you are listening to the Pharmacy podcast Network.
- 0:18Speaker 2: In a world where one size fits all medications dominate
- 0:22Speaker 2: the pharmaceutical industry, precision medicine brings a ray of hope
- 0:25Speaker 2: for those seeking customized healthcare. Pharmacists have a unique opportunity
- 0:29Speaker 2: to help people in need of specialized testing to ensure
- 0:32Speaker 2: medications work is intended. Welcome to Precision Help in PGX,
- 0:37Speaker 2: where we unravel the wonders of precision medicine and its
- 0:40Speaker 2: potential to revolutionize the way we approach pharmacy care. Get
- 0:44Speaker 2: ready to uncover the secrets behind pharmacogenomics and how it's
- 0:48Speaker 2: transforming lives one genome amount of time.
- 1:00Speaker 3: Our host, doctor Becky Winslow, and you're listening to the
- 1:02Speaker 3: Precision Health and PGX podcast. In case you didn't know,
- 1:07Speaker 3: my co hosts, doctor Banas Sarami and I decided to
- 1:11Speaker 3: rebrand the PGX for Pharmacist Podcasts to the Precision Health
- 1:16Speaker 3: and PGX Podcasts. Our goal in rebranding was to broaden
- 1:21Speaker 3: our listenership outside of pharmacy and broaden our content to
- 1:25Speaker 3: include non pharmacogenomics based precision health topics. No different than
- 1:31Speaker 3: we did on the PGX for Pharmacists podcasts. We will
- 1:35Speaker 3: continue to explore all things pharmacogenomics related, and our mission
- 1:40Speaker 3: still includes educating and advocating for PGX. We will continue
- 1:46Speaker 3: to accomplish this mission through exclusive interviews with highly qualified
- 1:51Speaker 3: and well experienced industry leaders that you've become accustomed to
- 1:55Speaker 3: hearing from. In this episode, we have two special guests us,
- 2:01Speaker 3: doctor Mary Wiseman and Miss Lexi Winsel. Doctor Wiseman is
- 2:06Speaker 3: a member of my Genius RX teen and a PGX
- 2:10Speaker 3: mentor for Manchester University School of Pharmacy students. Miss Winsle
- 2:15Speaker 3: is one of those students who is pursuing both her
- 2:18Speaker 3: farm d and her Masters of Pharmacogenomics. Together, we will
- 2:23Speaker 3: discuss Medicaid coverage a pharmacogenomics test and Medicaid's reimbursement of
- 2:30Speaker 3: a pharmacist time in the provision of PGX testing for
- 2:34Speaker 3: Medicaid beneficiaries. So, Mary, thank you so much for joining
- 2:40Speaker 3: me today. We've worked together for nearly five years now,
- 2:43Speaker 3: but it seems like only yesterday that as a fellow
- 2:47Speaker 3: you were helping a company interview me for a medical
- 2:51Speaker 3: Affairs world with that company, so we've come a long
- 2:54Speaker 3: way since then. Could you elaborate for our audience on
- 2:58Speaker 3: your education and experience specific the PGX. They will recognize
- 3:04Speaker 3: your expertise.
- 3:06Speaker 4: Definitely. Thank you, Becking so Yes.
- 3:09Speaker 5: After earning my fund, I completed a two year PGX
- 3:14Speaker 5: post doctoral fellowship with two longitudinal experiences, one in a
- 3:19Speaker 5: clinical diagnostic laboratory and the other one in a specialty pharmacy.
- 3:25Speaker 6: During the fellowship, I taught patients, providers, and advance pharmacy
- 3:29Speaker 6: practice experiences or happy students to know how to use
- 3:34Speaker 6: PGX testing to manage medication therapy and build a PGX
- 3:39Speaker 6: knowledge diabase.
- 3:41Speaker 4: Now I work for clinical diagnostic.
- 3:43Speaker 6: Clubs where I create and deliver medical content and training
- 3:49Speaker 6: on pharmacogenomics. I educate patients and providers on how PGX
- 3:55Speaker 6: can improve medication outcomes and advise them on PGX endorsement
- 4:00Speaker 6: and coverage issues.
- 4:04Speaker 3: Thanks for introducing yourself, Mary. Now let me introduce miss
- 4:08Speaker 3: Lexi Winsel. As I mentioned earlier. She's a dual degree
- 4:12Speaker 3: doctor in Pharmacy and Master's and pharmacogenomics student at Manchester
- 4:17Speaker 3: University School of Pharmacy. Lexi's been working with Mary and
- 4:22Speaker 3: me for six weeks now at in Genius r Rex
- 4:25Speaker 3: where she's been completing her elective APPY rotation. So welcome Lexi,
- 4:31Speaker 3: and thank you for joining us today. You've done some
- 4:34Speaker 3: interesting research on medicaidve PGX Medicaid coverage of PGX, then
- 4:39Speaker 3: I'm sure our listeners will find useful.
- 4:42Speaker 7: I know they'll find it useful.
- 4:43Speaker 3: Because these are some of the most common questions that
- 4:48Speaker 3: Mary and I field about pharmacogenomics. Is Medicaid coverage in
- 4:52Speaker 3: the pharmacist role? So before you elaborate on your research,
- 4:58Speaker 3: can you tell us more about your education and work
- 5:01Speaker 3: exparents thus far and how you intend to use your
- 5:05Speaker 3: Masters in PGX in your career.
- 5:08Speaker 1: Yeah, thanks for having me. So I knew I wanted
- 5:12Speaker 1: to go to school to become a pharmacist, so I
- 5:14Speaker 1: started doing my research on schools and I found that
- 5:18Speaker 1: Manchester University offered a dual degree program to get both
- 5:21Speaker 1: my farm d and Masters in PGX at the same time.
- 5:26Speaker 1: I really enjoyed learning about genetics in my undergrad experience,
- 5:31Speaker 1: and I thought it was a very interesting field that
- 5:33Speaker 1: seemed like the next big advancement in healthcare. So throughout
- 5:38Speaker 1: graduate school now I have been working as a pharmacy
- 5:41Speaker 1: intern in more traditional roles with involvement in retail and
- 5:46Speaker 1: hospital pharmacy. I would love to implement my masters in
- 5:51Speaker 1: PGX in the future in an ambulatory setting as PGX
- 5:56Speaker 1: becomes more accessible and hopefully coverage policies improve over time,
- 6:00Speaker 1: I would love to operate in a clinic that can
- 6:03Speaker 1: order PGX testing for patients and adjust their medication therapy.
- 6:09Speaker 3: So thanks Lexi for telling us about yourself. Based on
- 6:13Speaker 3: your future aspirations for pharmacogenomics and an ambulatory care clinic,
- 6:18Speaker 3: your research should serve you well in that position. Like
- 6:23Speaker 3: I mentioned earlier, your research has been centered around Medicaid
- 6:26Speaker 3: coverage or pharmacogenomics tests and what a pharmacist Medicaid reimbursed
- 6:33Speaker 3: roles can be when providing and billing for PGX related services.
- 6:39Speaker 7: And this is a very heavy topic. There's a lot
- 6:42Speaker 7: to unpack here.
- 6:44Speaker 3: You spend a lot of time focusing on the different
- 6:47Speaker 3: aspects of these questions.
- 6:49Speaker 7: So could you.
- 6:51Speaker 3: Start by defining pharmacogenomics, medicaid, and managed care organizations for
- 6:57Speaker 3: our audience listeners who may not be familiar with these terms.
- 7:02Speaker 1: Yeah. Absolutely, So let's start with pharmacogenomics and why it's important. So,
- 7:09Speaker 1: pharmacogenomics is the study of how an individual's genetics can
- 7:13Speaker 1: influence their response to medications. It examines how different genetic
- 7:18Speaker 1: variations can impact the metabolism of medications, which can directly
- 7:22Speaker 1: be related to the likelihood of experiencing adverse events the
- 7:27Speaker 1: safety and the efficacy of medications. This can provide clinical
- 7:32Speaker 1: utility by optimizing medication selection based on safety and efficacy,
- 7:37Speaker 1: and therefore enhancing clinical decision making. The next important piece
- 7:43Speaker 1: is Medicaid. So Medicaid is a joint federal and state
- 7:48Speaker 1: program that provides health coverage to millions of individuals. The
- 7:52Speaker 1: federal government has its own general rules that all state
- 7:56Speaker 1: Medicaid programs must follow. However, each state runs its own
- 8:01Speaker 1: program as well, so that means that eligibility requirements and
- 8:05Speaker 1: benefits can often vary from state to state. Lastly, i'll
- 8:10Speaker 1: briefly define what managed care organizations are or MCOs for short.
- 8:16Speaker 1: MCOs are entities that manage and coordinate healthcare services for
- 8:20Speaker 1: Medicaid beneficiaries. They work with the state Medicaid program to
- 8:25Speaker 1: administer benefits to the Medicaid recipients. Medicaid beneficiaries will typically
- 8:31Speaker 1: enroll in a specific MCO, which then becomes responsible for
- 8:35Speaker 1: coordinating their healthcare services. Some examples of some well known
- 8:40Speaker 1: MCOs could include Anthem, Blue Cross, Blue Shield, United Healthcare, Humana, etc.
- 8:47Speaker 1: An important thing to note is that although all MCOs
- 8:51Speaker 1: fall under Medicaid, they all have their own individual coverage
- 8:55Speaker 1: policies that can vary from MCO to MCO. We'll be
- 8:59Speaker 1: able to discuss that a little bit more in depth
- 9:02Speaker 1: later in our discussion.
- 9:05Speaker 4: Thank you Lexi for defining these terms for us.
- 9:09Speaker 6: Please briefly discuss the process of navigating MCO websites to locate, read,
- 9:15Speaker 6: and comprehend MCOs pharmacogenomics coverage and reimbursement policies, as that
- 9:21Speaker 6: can be tedious and dunting for someone not experienced in
- 9:25Speaker 6: doing so.
- 9:27Speaker 1: Of course, so navigating different insurance websites for coverage policies
- 9:33Speaker 1: and detailed information can be very time consuming and frustrating
- 9:38Speaker 1: at times for patients and providers. While searching for coverage
- 9:42Speaker 1: policies related to pharmacogenomics services, I found that the best
- 9:47Speaker 1: approach was to start with the search tool that's typically
- 9:50Speaker 1: available on an MCO's website. I would use keywords such
- 9:54Speaker 1: as pharmacogenomics or pharmacogenetics to search for specific policies but
- 10:00Speaker 1: unfortunately that did not always take me directly to their
- 10:04Speaker 1: coverage policy. Another quick approach may be typing into your
- 10:10Speaker 1: search engine, for example, does United Healthcare cover pharmacogenomics in Ohio?
- 10:16Speaker 1: And then typically that will pull up some of the
- 10:19Speaker 1: coverage policies related to PGX within that MCO. Lastly, I
- 10:24Speaker 1: recommend MCO policy readers take advantage of the control f
- 10:29Speaker 1: function while positioned on the MCO's PGX policy to search
- 10:34Speaker 1: for keywords such as SIP two D six or specific
- 10:37Speaker 1: drug names associated with PGX such as colo pedigril to
- 10:42Speaker 1: quickly navigate what can be lengthy documents. This approach works
- 10:47Speaker 1: because many MCOs define their coverage and reimbursement by specific
- 10:51Speaker 1: pharmaco genes and drugs. However, this method may not always
- 10:56Speaker 1: be effective for more ambiguous MCO policies.
- 11:01Speaker 4: Thank you Lexi and the certainly very helpful information for us. Now,
- 11:07Speaker 4: what did you find a Medicaid coverage of PGX?
- 11:11Speaker 1: Yeah, So, as we mentioned before, each state has their
- 11:14Speaker 1: own Medicaid program which allows for coverage of PGX to
- 11:19Speaker 1: vary from state to state. Additionally, the variations can continue
- 11:24Speaker 1: based on the different MCOs within that state. So some
- 11:28Speaker 1: MCOs are very limited and specific in their coverage. Some
- 11:32Speaker 1: MCOs provide rather ambiguous statements about their coverage, and some
- 11:37Speaker 1: still classify PGS as investigational and therefore provide no coverage. Unfortunately,
- 11:44Speaker 1: over the past month of working with you, I did
- 11:48Speaker 1: not have the time to investigate the specific details and
- 11:51Speaker 1: variations of MCOs in all fifty states, but I did
- 11:55Speaker 1: focus primarily on Pennsylvania and Ohio.
- 12:00Speaker 3: So, LEXI you dove into the different MCOs in Pennsylvania
- 12:05Speaker 3: and Ohio during your research. What are the different MCOs
- 12:10Speaker 3: in Pennsylvania and how do their coverage policies differ with
- 12:15Speaker 3: I mean within Pennsylvania.
- 12:18Speaker 1: Yeah, So the MCOs in Pennsylvania include Emera Health, Keystone,
- 12:25Speaker 1: Guy Singer, United Healthcare, UPMC Health Partners, and high Mark Healthcare.
- 12:32Speaker 1: They all have different coverage policies, So I'll go ahead
- 12:35Speaker 1: and provide some details on a few of them to
- 12:38Speaker 1: give you an idea of how those policies can vary.
- 12:42Speaker 1: So I found that Ameera Health, Keystone, and high Mark
- 12:46Speaker 1: Healthcare all had the exact same coverage policy in relation
- 12:50Speaker 1: to PGX testing. They will cover a once per lifetime
- 12:54Speaker 1: test of SIP four fifty polymorphisms for their members who
- 12:59Speaker 1: have a Q ordinary syndrome and our undergoing percutaneous coronary
- 13:04Speaker 1: intervention when clopidigrill is a treatment option. On the other hand,
- 13:10Speaker 1: United Healthcare will cover PGX multigene panels, which includes five
- 13:16Speaker 1: or more genes that are used to guide therapy decisions
- 13:19Speaker 1: for antidepressants and antipsychotic medications, only when all of the
- 13:26Speaker 1: following CRITERIAMT one, the individual has a diagnosis of major
- 13:32Speaker 1: depressive disorder or generalized anxiety disorder, and the individual has
- 13:37Speaker 1: failed at least one prior medication to treat their condition,
- 13:42Speaker 1: and the multigene panel has no more than fifteen relevant genes.
- 13:47Speaker 1: So in these examples you can see how specific these
- 13:51Speaker 1: eligibility requirements can be.
- 13:55Speaker 3: You're exactly right, Lexy, those coverage policies are very specific.
- 14:00Speaker 3: I mean, in particular America Health, Keystone, and high Mark
- 14:05Speaker 3: with their mention that CYP two C one nine may
- 14:10Speaker 3: be tested for patients that have acute coronary syndrome who
- 14:14Speaker 3: are undergoing percutaneous coroinary intervention. So that's very specific about
- 14:21Speaker 3: the patient that they think the test is medically necessary
- 14:25Speaker 3: and the time to test that.
- 14:27Speaker 7: Patient for that gene.
- 14:30Speaker 3: You mentioned that there are some ambiguous policies as well,
- 14:34Speaker 3: and I couldn't agree with you more. Mary, and I've
- 14:38Speaker 3: been doing this now for many, many years, and you're
- 14:40Speaker 3: exactly right. There's still some ambiguous policies out there.
- 14:44Speaker 7: Did you find that to.
- 14:45Speaker 3: Be the case with any of the MCOs in Pennsylvania?
- 14:49Speaker 1: Oh? Yes, I sure did so. An example of an
- 14:53Speaker 1: ambiguous coverage policy came from Geisinger. They consider PGX testing
- 14:59Speaker 1: to be medically necessary when the identification of a specific
- 15:04Speaker 1: gene marker is noted to be clinically necessary before initiating
- 15:08Speaker 1: therapy by the FDA as noted in the indication section
- 15:13Speaker 1: of the prescribing information, and or it is supported by
- 15:17Speaker 1: the NCCAN Guidelines, which is the National Comprehensive Cancer Network.
- 15:23Speaker 1: So this policy is vague and unclear because not all
- 15:27Speaker 1: of the products included in the FDA information includes specific
- 15:34Speaker 1: actions to be taken based on biomarker information. A decent
- 15:39Speaker 1: amount of it is just the FDA acknowledging that there
- 15:41Speaker 1: may be an association. The indication section of the FDA's
- 15:46Speaker 1: prescribing information is really the approved usage section on a
- 15:50Speaker 1: package insert. Since PGX is still a new and involving field.
- 15:56Speaker 1: It has not come far enough yet for the FDA
- 15:58Speaker 1: to state its approval on PGX testing for many medications.
- 16:03Speaker 1: And lastly, as we mentioned that NCC and guidelines don't
- 16:07Speaker 1: really have anything to do with PGX testing. We know
- 16:11Speaker 1: that genetics can play a large role in cancer development
- 16:14Speaker 1: and treatment, but again those guidelines are specific to cancer only.
- 16:21Speaker 3: So you mentioned that you were also focusing on policies
- 16:24Speaker 3: in Ohio. What are the MCOs in Ohio and how
- 16:29Speaker 3: much do their policies differ from Pennsylvania.
- 16:33Speaker 1: Yeah, so the MCOs in Ohio include Ameera health Care, Source, Anthem,
- 16:39Speaker 1: United Healthcare, Buckeye Healthcare, Molina Healthcare, and Humana. I found
- 16:46Speaker 1: that ameerahealth and United Healthcare had the exact same policy
- 16:50Speaker 1: in Ohio that.
- 16:51Speaker 4: They had in Pennsylvania.
- 16:53Speaker 1: However, Anthem had another vague policy. They will cover one
- 16:59Speaker 1: genotyping for the appropriate biomarker recognized by the FDA approved
- 17:03Speaker 1: therapies and associated biomarkers when all of the following conditions
- 17:08Speaker 1: are met, so the medication for which genotyping is being
- 17:13Speaker 1: done is the most appropriate treatment for the individual's underlying condition.
- 17:18Speaker 1: And the PGX test has demonstrated analytical and clinical validity
- 17:23Speaker 1: and clinical utility for the individual, including consideration of the
- 17:29Speaker 1: frequency of relevant alleles in the individual's subgroup, and the
- 17:34Speaker 1: biomarker testing is focused on the specific genetic polymorphisms relevant
- 17:41Speaker 1: to guiding treatment for the individual's condition. They then provide
- 17:46Speaker 1: the FDA's table of associated biomarkers as a reference. I
- 17:51Speaker 1: would like to point out how they mentioned that it
- 17:53Speaker 1: must be the most appropriate treatment. They do not provide
- 17:58Speaker 1: any context on how that is determined, and as we know,
- 18:02Speaker 1: treatment guidelines can differ in providers will consider many things
- 18:06Speaker 1: when deciding what is considered most appropriate, things such as adherents,
- 18:11Speaker 1: dosage form, adverse events, cost, etc.
- 18:17Speaker 8: Thank you, Leccine. Thank you for explaining that. And you
- 18:21Speaker 8: also mentioned that earlier that some MCOs provide no coverage
- 18:27Speaker 8: for PGX testing.
- 18:29Speaker 6: Did you, for example, find any policies like that while
- 18:32Speaker 6: researching MCOs in Pennsylvania and Ohio.
- 18:37Speaker 1: Yeah, I did find some policies that offered no coverage
- 18:41Speaker 1: for PGX testing. And I also found a lot of
- 18:45Speaker 1: instances where prior authorizations were thrown into the mix, which
- 18:49Speaker 1: we know how that can complicate things even further. So,
- 18:52Speaker 1: for example, Anthem in Ohio recently released a statement that
- 18:58Speaker 1: although they currently offer for the coverage for everything that
- 19:01Speaker 1: we just discussed, effective May first of twenty twenty four,
- 19:06Speaker 1: prior authorization rules will apply to all pharmacogenomics testing now.
- 19:12Speaker 1: Right now, I was unable to find more specific information
- 19:16Speaker 1: on this, but we can anticipate seeing some changes in
- 19:19Speaker 1: their coverage policy within the next month. I also found
- 19:24Speaker 1: that UPNC in Pennsylvania classifies pharmacogenomics as investigational and experimental,
- 19:32Speaker 1: therefore making it not medically necessary and not something that
- 19:35Speaker 1: they would cover.
- 19:39Speaker 4: Thank you for providing such an important information update for us.
- 19:43Speaker 6: So now I guess the burning question enbody will be
- 19:47Speaker 6: waiting for that is what does the means for the
- 19:50Speaker 6: pharmacists and how can we become more involved.
- 19:55Speaker 1: Yeah, so, now that we have an idea of MEDICAIDS
- 19:59Speaker 1: coverage of pharmacogenomics, we can start to investigate the pharmacist
- 20:04Speaker 1: role and how that may also vary from state to state.
- 20:08Speaker 1: So pharmacists are not recognized as providers in every state,
- 20:12Speaker 1: and that alone can play an important role in what
- 20:14Speaker 1: a pharmacist is able to do. In states that do
- 20:18Speaker 1: recognize pharmacists as providers, there may still be differing special
- 20:23Speaker 1: requirements to enroll as a provider within Medicaid. I chose
- 20:27Speaker 1: to focus on Pennsylvania because pharmacists actually just gain provider's
- 20:32Speaker 1: status on March first of twenty twenty four, so now
- 20:36Speaker 1: pharmacists and Pennsylvania are recognized as a mid level practitioner
- 20:40Speaker 1: who can provide and bill for Medicaid fee for services.
- 20:45Speaker 1: Pharmacists cannot independently prescribe on their own, but they can
- 20:49Speaker 1: prescribe under a collaborative practice agreement, which we can get
- 20:53Speaker 1: into more detail on that later, but for now, pharmacists
- 20:57Speaker 1: in Pennsylvania can build for Medicaid Therapy Management or MTM
- 21:02Speaker 1: for short, and this is where pharmacists would be able
- 21:06Speaker 1: to order PGX testing. Under that collaborative practice agreement, they
- 21:11Speaker 1: can also build for immunization administration, and alcohol or substance
- 21:16Speaker 1: abuse screening and intervention. The other state I focused on
- 21:20Speaker 1: was Ohio, and pharmacists in Ohio gained provider status in
- 21:25Speaker 1: twenty nineteen and they can build for MTM services, which
- 21:31Speaker 1: again includes the ordering tests for pharmacogenomics, immunization administration, and
- 21:39Speaker 1: administering medications. Ohio pharmacists also cannot prescribe unless they're working
- 21:45Speaker 1: under a collaborative practice agreement.
- 21:50Speaker 4: That's great, great information.
- 21:52Speaker 6: And before we go into more detail on how this
- 21:56Speaker 6: relates to pharmaco genomics, can you briefly explain what is.
- 22:00Speaker 4: A collaborative practice agnment?
- 22:03Speaker 1: Yeah, So, a collaborative practice agreement or CPA for short,
- 22:09Speaker 1: allows pharmacists to provide patient care and drug therapy management
- 22:13Speaker 1: services under an agreement between the pharmacist and a prescriber.
- 22:19Speaker 1: This is relevant across the United States because now all
- 22:22Speaker 1: fifty states recognize CPAs between pharmacists and prescribers. However, there
- 22:28Speaker 1: may be some differences between each state. These differences could
- 22:33Speaker 1: include requirements of continuing education, liability insurance, documentation of services,
- 22:42Speaker 1: and a patient agreement to receive services as part of
- 22:45Speaker 1: the CPA. While CPAs may vary from state to state,
- 22:50Speaker 1: what a pharmacist can do typically includes initiating, modifying, or
- 22:55Speaker 1: discontinuing medications, ordering and interpreting laboration, tory tests, patient assessments,
- 23:02Speaker 1: patient education, monitoring patient outcomes, and documentation of patient encounters,
- 23:08Speaker 1: treatment plans and interventions.
- 23:13Speaker 3: So, Lexi, you've told us a lot about CPAs and
- 23:17Speaker 3: what they empower pharmacists to do. So let's drill down
- 23:22Speaker 3: into pharmacogenomics through collaborative practice agreements. How can pharmacists play
- 23:31Speaker 3: important roles in the provision of clinical pharmacogenomics.
- 23:36Speaker 1: Yeah, so, CPAs are a huge deal because not only
- 23:40Speaker 1: does it allow room for pharmacists to step in as
- 23:42Speaker 1: providers and utilize their clinical knowledge and abilities, but it
- 23:46Speaker 1: also delegates the workload for the prescriber and creates more
- 23:50Speaker 1: access to health care for patients. So, in relation to pharmacogenomics,
- 23:56Speaker 1: pharmacists under a CPA may assess a patient for their
- 24:00Speaker 1: medical necessity of PGX testing. They can order a PGX
- 24:05Speaker 1: test and manage the patient's medications using the test results.
- 24:10Speaker 1: In brief, pharmacists are trained to identify medication therapy problems
- 24:14Speaker 1: and correct those problems. If we view MTMS as the toolbox,
- 24:20Speaker 1: then within it we have tools like laboratory tests and
- 24:23Speaker 1: biometric screening to aid in medication therapy management. Pharmacogenomics is
- 24:29Speaker 1: one such laboratory test in that MTM toolbox that pharmacists
- 24:33Speaker 1: can use. Overall, pharmacist combination of medical expertise, drug knowledged
- 24:40Speaker 1: and the collaborative approach makes them a well suited to
- 24:44Speaker 1: handle PGX services and contribute to personalized medicine initiatives.
- 24:51Speaker 6: So, now that we have an idea of Medicaid coverage
- 24:54Speaker 6: of pharmacogenomics tests and what roles a pharmacist can play
- 25:00Speaker 6: in the prevision of PGX, let's examine how Medicaid's reimbursement
- 25:05Speaker 6: of the pharmacist time is compared to the actual time
- 25:10Speaker 6: the pharmacist puts into the provision of FIGX.
- 25:15Speaker 1: Yeah, so that is the overarching question here. Now that
- 25:19Speaker 1: we know Medicaid coverage for the test can vary and
- 25:23Speaker 1: CPAs are recognized across all fifty states, let's tie it
- 25:27Speaker 1: all together and walk through an example case. So let's
- 25:32Speaker 1: say we have a patient who has been diagnosed with
- 25:35Speaker 1: major depressive disorder and that patient has United Healthcare, which
- 25:41Speaker 1: manages their Medicaid benefits. This patient has tried and fact
- 25:46Speaker 1: failed as the talpram or lexipro previously. For this example,
- 25:52Speaker 1: let's say you are a pharmacist operating under a CPA
- 25:56Speaker 1: in Pennsylvania. According to United Healthcare's coverage policy, this patient
- 26:02Speaker 1: meets the medical necessity requirements for UHC to reimburse a
- 26:07Speaker 1: multi gene PGX panel. Since you are operating under a CPA.
- 26:12Speaker 1: As a pharmacist, you can order this multigene panel and
- 26:17Speaker 1: bill for fifteen minutes of their time with code nine
- 26:20Speaker 1: nine six zero five, which is approximately a fifty dollars reimbursement. Additionally,
- 26:27Speaker 1: you can discuss the results with the patient and create
- 26:30Speaker 1: a new treatment plan in a follow up fifteen minute
- 26:33Speaker 1: appointment where you could build code nine nine six zero
- 26:37Speaker 1: six for approximately a forty dollars reimbursement.
- 26:41Speaker 3: Thanks Lexie for giving us that example of reimbursement for
- 26:46Speaker 3: the PGX test and reimbursement of the pharmacist time in
- 26:52Speaker 3: the provision of that PGX test, So just to recap
- 26:57Speaker 3: for our audience and because we're running out of time.
- 27:03Speaker 3: Medicaid coverage of PGS tests varies depending on the.
- 27:07Speaker 7: State and the MCO.
- 27:10Speaker 3: Some MCOs cover only specific drug gene pairs or health conditions,
- 27:15Speaker 3: others provide ambiguous coverage, and others provide no coverage. And lastly,
- 27:21Speaker 3: pharmacists can play many critical roles in pj's implementation and utilization,
- 27:28Speaker 3: but current direct Medicaid reimbursement to the pharmacists for their
- 27:33Speaker 3: time is limited and may not be financially sustainable to
- 27:38Speaker 3: the individual pharmacists who's billing directly. Now, with that said,
- 27:45Speaker 3: one goal for managed care organizations is to manage a
- 27:49Speaker 3: patient's health such that the cost for the patient's care
- 27:53Speaker 3: does not exceed the dollar amount they are paid to
- 27:56Speaker 3: manage the patient. In this context, the pharmacists can indirectly
- 28:02Speaker 3: pay their own salary in the money that they help
- 28:06Speaker 3: the MCO save by reducing poor medication outcomes such that
- 28:12Speaker 3: the cost for the patient's care does not exceed the
- 28:15Speaker 3: money Medicaid pays the MCO for the patient. An example
- 28:20Speaker 3: of this scenario would be a pharmacist who orders a
- 28:24Speaker 3: PGX test for an MCO patient and managing their medications
- 28:30Speaker 3: such that the patient does not have to visit the
- 28:33Speaker 3: emergency room due to an average drug reaction that may
- 28:39Speaker 3: not have been known or there may be no warning
- 28:43Speaker 3: signs for prior to the patient taking the medication without
- 28:47Speaker 3: a PGX test.
- 28:49Speaker 7: Essentially, the pharmacists.
- 28:52Speaker 3: Can save the MCO the money that they would have
- 28:55Speaker 3: to spend for that patient to go to the emergency
- 28:59Speaker 3: room visit for that average a drug event, and that
- 29:02Speaker 3: costs a lot less than what it would cost the
- 29:05Speaker 3: MCO to pay the pharmacists for their time in the
- 29:09Speaker 3: provision of pharmacogenomic testing for that drug.
- 29:13Speaker 7: So, as I mentioned earlier.
- 29:16Speaker 3: Just a few minutes back, we've run out of time,
- 29:19Speaker 3: and so I just want to thank Mary and Lexi
- 29:23Speaker 3: for joining us on this episode, and most of all,
- 29:26Speaker 3: thank you audience for tuning in. We hope you've learned
- 29:30Speaker 3: about MCO's PGX reimbursement and the pharmacist role. We do
- 29:35Speaker 3: a lot of PGX in here on the Precision Health
- 29:37Speaker 3: in PGX podcasts, PGX science, clinical application and business, and
- 29:43Speaker 3: we hope you learned and you continue to learn from
- 29:47Speaker 3: us in further episodes.
- 29:49Speaker 7: We love to hear from you. What can we teach you?
- 29:52Speaker 7: Drop us a message on LinkedIn and just let us know.
- 29:55Speaker 3: Please also share the link to this podcast episode with
- 29:58Speaker 3: everyone they to will know to tune in and listen
- 30:02Speaker 3: to the Precision Health and PGX podcasts, and if.
- 30:06Speaker 7: You have time, please leave us a review on.
- 30:08Speaker 3: Apple Podcasts or Spotify. You can visit us on pjxr
- 30:13Speaker 3: X dot com to listen to all of our episodes